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Abstract (246 words) 21 
Background 22 
Clinical staging of NSCLC helps determine prognosis and management of patients; few data 23 
exist on accuracy of clinical staging and the impact on treatment and survival of patients. 24 
We assessed whether participant or trial characteristics were associated with clinical staging 25 
accuracy as well as impact on survival.   26 
Methods 27 
We used individual participant data from RCTs, supplied for a meta-analysis of pre-operative 28 
chemotherapy (+/- radiotherapy) versus surgery alone (+/- radiotherapy) in NSCLC. We 29 
assessed agreement between clinical TNM (cTNM) stage at randomization and pathological 30 
TNM (pTNM) stage, for participants in the control group.   31 
Results 32 
Results are based on 698 patients who received surgery alone (+/- radiotherapy) with data 33 
for cTNM and pTNM stage.  46% of cases were cTNM stage I, 23% cTNM stage II and 31% 34 
cTNM stage IIIa.  cTNM stage disagreed with pTNM stage in 48% of cases, with 34% clinically 35 
understaged and 14% clinically over-staged.  Agreement was not associated with age 36 
(p=0.12), gender (p=0.62), histology (p=0.82), staging method (p=0.32) or year of 37 
randomisation (p=0.98).  Poorer survival in understaged patients was explained by the 38 
underlying pTNM stage. Clinical staging failed to detect T4 disease in 10% of cases and 39 
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This study demonstrates suboptimal agreement between clinical and pathological staging. 42 
Discrepancies between clinical and pathological T and N-staging could have led to different 43 
treatment decisions in 10% and 38% of cases respectively. There is therefore a need for 44 
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Background 48 
The clinical staging of non-small cell lung cancer (NSCLC) is of paramount importance in 49 
determining a patient’s prognosis, guiding treatment decisions and defining clinical trial 50 
eligibility, as well as allowing comparison between clinical trials. Incorrect staging of NSCLC 51 
may result in inaccurate prognostic information for patients and errors in patient 52 
management. After extra-thoracic metastases have been excluded, tumor and nodal staging 53 
are critical in making treatment decisions, as patients with N0 and N1 involvement are 54 
generally candidates for surgery. Patients with ipsilateral mediastinal disease (N2) are a 55 
heterogeneous group and may be offered chemo-radiation therapy or surgery (with pre-56 
operative or post-operative chemotherapy). Patients with contra-lateral (N3) mediastinal (or 57 
supraclavicular) nodal disease are offered chemo-radiation therapy or palliative treatment 58 
options. Therefore, clinical under-staging, i.e. staging that misses mediastinal metastases or 59 
mediastinal invasion of the primary lesion may risk the patient undergoing radical treatment 60 
of the primary lesion for no benefit. Conversely, incorrect clinical over-staging of mediastinal 61 
disease may result in surgery being denied to an otherwise operable patient. The current 62 
guidance from the Union for International Cancer Control (UICC)
1
 suggests that when there 63 
is doubt about stage, the less advanced, or lower category should be chosen. 64 
The emergence of techniques such as stereotactic body radiotherapy
2
 (SABR) and 65 
radiofrequency ablation
3
 (RFA) to treat early stage NSCLC in medically inoperable patients 66 
has further highlighted the importance of accurate clinical staging. Applying local non-67 
surgical treatments without the benefit of systematic lymph node dissection runs the risk of 68 
being futile if there is clinical under-staging with unrecognized mediastinal or systemic 69 
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Although the importance of accurate clinical staging is clear and the performance 71 
characteristics of individual tests in lung cancer staging are known, fewer data exist on the 72 
accuracy of clinical staging of NSCLC and how this relates to the staging techniques 73 
employed. Three studies that have been reported all show high levels of inaccurate clinical 74 
staging; however none have demonstrated the impact of erroneous staging on clinical 75 
outcome.  A prospective study of 383 patients with potentially resectable NSCLC 76 
demonstrated that clinically unsuspected N2 disease was found in 14% of patients. Despite 77 
routine use of PET-CT scanning
4
, a post-hoc analysis of 67 patients from the control arm of 78 
the MRC LU22
5
 trial of pre-operative chemotherapy suggested that nodal staging was 79 
inaccurate in 25% (95% CI 15 – 36%) of patients who underwent PET-CT scanning and 80 
mediastinoscopy
6
. A recently published study comparing clinical and pathological TNM data 81 
collected for 2336 patients included in the Dutch Lung Surgery Audit
7
, showed that only 54% 82 
of patients were clinically staged accurately and no comment could be made on whether 83 
this impacted on patient survival outcomes.  Thus, to investigate further, we used individual 84 
participant data (IPD) from trials supplied for a systematic review and meta-analysis of pre-85 
operative chemotherapy in non-small cell lung cancer to assess the accuracy of clinical 86 
staging, factors that may affect inaccuracy and how inaccuracy might impact on treatment 87 
decisions and survival. 88 
 89 
Methods 90 
To be eligible for inclusion in the original IPD meta-analysis
8
, trials should have randomized 91 
patients with NSCLC to pre-operative chemotherapy followed by surgery (+/- post-operative 92 
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are presented elsewhere
8
.   IPD were collected for fifteen eligible randomized controlled 94 
trials and included 2385 patients with non-small cell lung cancer
8
. However, only data from 95 
patients from the control arm in these trials were used in this analysis, to ensure that any 96 
difference between clinical and pathological staging could not have been influenced by pre-97 
operative chemotherapy. Included RCTs used different editions of TNM staging and these 98 
changes over time were taken into account (e-appendix 1). 99 
Data on age, gender, clinical staging techniques, clinical TNM stage, extent of resection, 100 
pathological TNM stage, histology, performance status, treatment group and dates of 101 
randomization, last-follow-up and death were collected.  We approached study 102 
investigators for permission to use these data for these analyses and for clarification where 103 
staging methods were unclear in the original trial protocol or manuscript. 104 
 105 
Statistical analysis 106 
To assess agreement between clinical TNM stage (cTNM) and pathological TNM stage 107 
(pTNM), a simple percentage agreement was calculated.  Agreement between clinical and 108 
pathological stage was also calculated using a weighted Cohen’s kappa, which takes into 109 
account both agreement by chance and the degree of disagreement.  Kappa statistics were 110 




.  111 
To assess whether or not patient and trial characteristics might be associated with any 112 
cTNM staging inaccuracy age, gender, histology, year of randomisation and staging method 113 
were included in a multivariate logistic regression model. Histology was classified into 114 
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scan with or without a chest X-ray or CT scan plus any other staging method, as there were 116 
insufficient data to do this in more detail. Staging method correlated strongly with year of 117 
randomization, so we only included the former in our primary analysis.  However, a 118 
sensitivity analysis was also performed, where staging method was replaced with year of 119 
randomization.  We generated Kaplan-Meier curves for overall survival based on patients 120 
who were clinically under-staged, clinically over-staged and for those whose cTNM and 121 
pTNM agreed, and compared these using a log-rank test, stratified by trial and subsequently 122 
also pathological stage.  The accuracy of clinical T stage and nodal status were considered 123 
separately to help pinpoint which disagreements could have influenced treatment decisions.   124 
 125 
Role of the funding source 126 
Funded by the UK Medical Research Council MC_UU_12023/28.  The sponsors of the 127 
original trials had no role in this study design, data collection, data analysis, data 128 
interpretation, or writing of the report. No IRB approval is needed. 129 
 130 
Results 131 
Fifteen RCTs were included in the original IPD systematic review and meta-analysis of pre-132 
operative chemotherapy followed by surgery versus surgery alone.  Nine trials
5,11-18
 133 
(randomising 1,586 patients in total) included data on both cTNM and pTNM stage, 134 
providing 698 control-arm patients for analysis (Table 1). These RCTs accrued patients 135 
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Clinical staging protocols varied between the trials (Table 1). One trial 
11
(which recruited 137 
patients between 1987 and 1993) used a chest x-ray and mediastinoscopy only. More recent 138 
trials used CT scans and PET-CT, but no trial utilised PET-CT scanning routinely, such that 139 
only 67 patients included in the analysis underwent PET-CT.  There was also variation 140 
between trials in the surgical methods used (Table 1). 141 
Of the 698 patients included, 318 (46%) were cTNM stage I (83% of which were Ia), 160 142 
(23%) were cTNM stage II (91% of which were IIa), and 218 (31%) were cTNM stage IIIa 143 
(Table 2). Only 2 patients were classed as cTNM stage IIIB, and were therefore not included 144 
in the regression or survival analyses.  A more detailed breakdown is given in e-appendix 2. 145 
Agreement between cTNM and pTNM staging was low (52%, weighted Cohen’s kappa=0.35 146 
(95% CI 0.30 to 0.40) (Table 2).  In 34% of cases, patients were clinically under-staged, and in 147 
14% of cases, patients were clinically over-staged (Table 2). In the main regression analysis, 148 
age (p=0.12), gender (p=0.62), histology (p=0.82) or the staging method (p=0.32) were not 149 
significantly associated with the accuracy of cTNM staging and in a sensitivity there was no 150 
association with year of randomization (p=0.98; e-appendix 3). 151 
Survival varied with the accuracy of cTNM staging. In particular, patients who were clinically 152 
under-staged appeared to have poorer survival than those who were clinically over-staged 153 
or those for whom cTNM and pTNM staging agreed (log-rank test stratified by trial 154 
p<0.0001; Figure 1).  However, this is driven by the underlying pTNM stage (log-rank test 155 
stratified by trial and pathological stage p=0.54), which is more clearly illustrated in Figure 2.  156 
In particular, 44% of patients classed as cTNM stage I were pTNM stage II-IV, and 33% of 157 
patients classed as cTNM stage II were pTNM stage III-IV, explaining their lower survival 158 












ACCEPTED MANUSCRIPTNavani –Accuracy of staging in NSCLC 
Agreement was low between clinical and pathological T stage (65%, weighted Cohen’s 160 
kappa=0.33 (95% CI 0.27 to 0.39), Table 3) and N stage (62%, weighted Cohen’s kappa=0.42, 161 
(95% CI 0.37 to 0.48), Table 4). Specifically, clinical staging failed to detect T4 disease in 10% 162 
of patients (Table 3), and nodal disease in 19% of patients. In addition, 12% were judged 163 




Results summary 168 
We found that cTNM stage disagreed with pTNM stage in around a half of patients, and was 169 
not clearly associated with age, gender, histology, the staging method used or year of 170 
randomization.  The discrepancies between clinical and pathological T-staging and N-staging 171 
could have led to different treatment decisions in 10% and 38% of cases respectively.  172 
 173 
Strengths 174 
To our knowledge, this is the first time IPD from major RCTs have been combined to assess 175 
the accuracy of staging in stage I-III NSCLC.  Whilst the randomized controlled trials included 176 
did not intend to evaluate staging, with the agreement of those who provided the data, this 177 
novel methodology provided us with a valuable opportunity to investigate more reliably the 178 
accuracy of clinical TNM staging. We could take advantage of per protocol clinical staging 179 
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patient. Also, data from randomized trials are less susceptible to the selection biases that 181 
can affect cohort studies
19,20
.  Using IPD has enabled us to restrict the analysis to the control 182 
arms of these trials, thus avoiding confounding by treatment received and, in particular, 183 
potential downstaging from use of pre-operative chemotherapy. 184 
For the first time, this study also demonstrates the impact of the inaccuracy of clinical 185 
staging on patient survival outcomes. Importantly, the impact of staging accuracy on clinical 186 
decision making is also demonstrated using unselected data. The poorer survival seen in 187 
clinically understaged patients was explained by the underlying pTNM stage. 188 
 189 
Limitations 190 
Over time the trials included here used increasingly sophisticated staging methods, but 191 
surprisingly, a significant improvement in accuracy was not seen.  However, many of the 192 
staging methods utilised in the included trials may now be considered sub-optimal
21
. Earlier 193 
studies employed CT scanning and mediastinoscopy while the most recent trial used 194 
additional PET-CT, but none used endosonography. Despite this, our staging accuracy results 195 
are remarkably similar to those from the audit of the quality of staging in Dutch patients
7
 196 
which included routine use of PET-CT and endosonography and included patients from 197 
January 2013-December 2014. Indeed, of the patients included in our analysis that did 198 
undergo PET-CT, a quarter of cases were still understaged and this is discussed elsewhere
6
.  199 
While PET-CT or endosonography was not routinely utilized in the trials included in this 200 
meta-analysis, this practice reflects current American College of Chest Physicians’ 201 
guidance
22
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endosonography. Although it is difficult to generalise, assuming the trial population reflects 203 
routine practice, the data here suggest that 44% of patients with clinical stage 1 disease 204 
might have more advanced disease diagnosed post-operatively.. A further limitation is that 205 
intra-operative pathological staging protocols may have varied and are unlikely to be as 206 
comprehensive as currently recommended
23
. However, incomplete pathological staging 207 
would only serve to reduce the extent of nodal staging inaccuracy.  208 
 209 
Context 210 
The advent of stereotactic radiotherapy and radiofrequency ablation for the treatment of 211 
early stage NSCLC has highlighted the importance of accurate nodal staging. These newer 212 
techniques are used for the treatment for early stage lung cancer but, in contrast to surgery, 213 
do not provide pathological staging information. In a study of relapse of NSCLC following 214 
stereotactic radiotherapy or surgery, there were twice as many recurrences in local lymph 215 
nodes in patients undergoing stereotactic radiotherapy compared to surgery
24
, emphasizing  216 
the importance of accurate nodal staging prior to SABR. 217 
When surgery is undertaken and pathological staging is available, prior invasive mediastinal 218 
sampling may take on less significance if we assume that surgery followed by adjuvant 219 
chemotherapy is at least as effective as chemo-radiation. When considering stage II and III 220 
disease, inaccurate clinical staging may reduce the efficacy of surgery by failing to detect 221 
multi-station N2 or N3 disease. For patients undergoing radical radiotherapy, imprecise 222 
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The most likely explanation for the low level of accuracy of clinical staging for patients with 224 
operable NSCLC is the sensitivity of the diagnostic tools employed.  Patients being 225 
considered for treatment with curative intent typically undergo CT and PET-CT imaging as 226 
well as mediastinal sampling when required. Using a 10mm short axis cut-off for significance 227 
of mediastinal nodes, the sensitivity of CT scanning in detecting mediastinal metastases is 228 
55%
22
.  PET-CT has a sensitivity of 77-81%
25
 and may vary according to brand of scanner and 229 
histology. In a systematic pooled analysis of 9267 patients, mediastinoscopy had a 230 
sensitivity of 78%
22
. Overstaging may occur with PET-CT unless current guidelines [22] are 231 
adhered to and PET positive findings are clarified by invasive sampling. More recently the 232 
introduction of endobronchial and endoscopic ultrasound has improved the clinical staging 233 
of patients with NSCLC, resulting in a reduction in futile surgery
26,27
 and potentially 234 
increased survival
28
 when employed routinely for patients with stage I-III disease.  235 
 236 
Implications 237 
These findings have implications for the care of patients with NSCLC, as well as appropriate 238 
selection of suitable patients for inclusion in clinical trials. Under-staging the T stage may 239 
mean that the patient undergoes surgery without the surgeon knowing the full extent of the 240 
primary disease, which may result in an incomplete resection. 10% of patients in our 241 
analysis were found to have previously unexpected T4 disease.  Erroneous nodal staging in 242 
patients without metastatic disease can similarly result in inappropriate treatment 243 
decisions, which can significantly impact on patient outcomes. Patients with nodal disease 244 
undetected by clinical staging methods may undergo futile surgery (or SABR) whereas 245 
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with full knowledge of nodal involvement. Conversely, if clinical staging overestimates the 247 
extent of nodal disease (114 (15%) of patients in this meta-analysis) then this may mean 248 
patients are denied potentially curative surgery. The data for this analysis were obtained 249 
from patients in controlled clinical trials, generally from centers with lung cancer expertise. 250 
Therefore, clinical staging accuracy in the wider population could well be worse.  251 
 252 
Conclusions 253 
The results of this analysis highlight some flaws in the clinical care of patients with NSCLC 254 
and emphasize the need for further research into techniques for improving staging accuracy 255 
for patients with stage I-III NSCLC.  256 
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Figure legends 
Table 1: Characteristics of included trials  
Table 2: Agreement between clinical and pathological TNM stage data  
Table 3: Agreement between clinical and pathological of T stage data 
Table 4: Agreement between clinical and pathological nodal status data 
Figure 1: Kaplan-Meier curves for overall survival for all trial data combined, by agreement 
of clinical TNM staging with pathological TNM staging 
Figure2: Kaplan-Meier curves for overall survival in clinically staged 1, 2 and 3 patients, by 
agreement of clinical TNM staging with pathological TNM staging 
e-appendix 1: Comparison of TNM staging systems 
e-appendix 2: Flowchart describing clinical and pathological agreement, clinical over staging 
and clinical under staging 




































60 32 32 87-93 4 Chest x-ray One or more positive nodal stations 
allowed. Patients with left lung tumors 
and paratracheal lymph node 




355 176 170 91-97 4 Chest x-ray, CT Mediastinal node dissection and node 




79 40 37 91-99 4 CT and 
mediastinoscopy 
Mediastinal lymph node exploration 
was encouraged: for right-sided lesions, 
this included 2R, 4R, 7, 8, 9. For left-




62 31 31 93-98 4 CT Surgery was either lobectomy, 
bilobectomy, or 
pneumonectomy along with systematic 
mediastinal lymph node dissection. 
Finland 
2003(15) 
62 32 23 95-99 4 CT ‘Local surgery’ 
MRC 
LU22(UK)(5) 
519 261 194 97-05 5/6 Bronchoscopy, 
mediastinoscopy 
and CT, PET  
At cervical mediastinoscopy, the 
following lymph node stations will, 
wherever possible, be sampled: 2R, 2L, 
4R, 4L, 7 
SWOG S9900 
(USA)(16) 
354 174 170 99-04 5/6 Chest x-ray and 
CT 
All accessible hilar (level 10) lymph 













mediastinal lymph node sampling 
should be performed…for right-sided 
lesions, this includes 2R, 4R, 7, 8 and 9. 
For left-sided lesions, this includes 4L, 
5, 6, 7, 8 and 9. 
China 
2002(17) 




Surgery consisted of radical lung 
resection and systematic mediastinal 
lymph node dissection 
China 
2005(18) 




Lobectomy or pneumonectomy with 
systematic lymph node dissection 
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CT – Computed tomography 
IPD – Individual participant data 
MRC – Medical Research Council 
NSCLC – Non-small cell lung cancer 
PET-CT - Positron emission tomography–computed tomography 
RCT – Randomised controlled trial 
RFA - Radiofrequency ablation 
SABR - Stereotactic body radiotherapy  
UCL – University College London 
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e-Table 1.   
Comparison of TNM staging systems  
 
4th edition (1987)(29) 5th edition (1997)(30), 6th edition 
(2002)(31)  
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cT < pT 
n=75 (32%) 
cN < pN 
n=100 (42%) 
cN > pN 
n=72 (72%) 
cT > pT 
n=17 (17%) 
cT > pT 
n=9 (9%) 
Unforeseen pN2+ 
n=103 (44% of 236) 
of which: 
n=10 (10%) pM1 
n=25 (24%) both cT < pT and cN < pN 
n=7 (7%) cT > pT 
 
cN > pN 
n=4 (5%) 
cN < pN 
n=1 (6%) 
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e-Table 2.   
Multivariate logistic regression; Factors that may predict staging agreement 
 
Predictor TNM stage 
 2 (df) p-value 
Histology 0.40 (2) 0.82 
Staging method 1.01 (1) 0.32 
Age 2.48 (1) 0.12 
Gender 0.24 (1) 0.62 
Overall* 4.22 (5) 0.52 
  
“Overall” compares the model with all covariates entered to the null model 
 
Sensitivity analysis with staging method replaced with year of accrual: 
 
Predictor TNM stage 
 2 (df) p-value 
Histology 0.48 (2) 0.79 
Year of randomisation 0.00 (1) 0.98 
Age 2.55 (1) 0.11 
Gender 0.19 (1) 0.66 
Overall* 3.21 (5) 0.67 
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